CAMBRIDGE, MA – Publicly-traded office space developer, owner and manager BXP has acquired a 271,000-square-foot laboratory/life sciences property in Cambridge, MA from Biogen for $592 million.
Biogen has signed a lease to continue occupying the entire six-story property, located at 125 Broadway, through April 2028.
BXP funded the purchase with cash and borrowings under its line of credit. The firm is currently evaluating opportunities to own the property with one or more joint-venture equity partners.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Ingrid Tunberg
Ingrid Tunberg sits on the editorial team as a coordinator and reporter for Real Estate Forum and GlobeSt.com. She is responsible for writing stories, assisting with industry awards and marketing nomination events. Previously, Ingrid worked as a copywriter across various industries throughout New York City and Chicago.
